Valsts: Lielbritānija
Valoda: angļu
Klimata pārmaiņas: HMA (Heads of Medicines Agencies)
febantel 150 mg, praziquantel 50 mg, pyrantel 50 mg
CEVA Animal Health
QP52AA51
Tablet
praziquantel, combinations
Dogs
2011-11-23
Revised: December 2011 AN: 00108/2011 Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT X-SPECTRA Flavoured tablets for medium and small dogs [UK] CESTEM F tablets for dogs [FR] 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains: ACTIVE SUBSTANCES: Febantel ............................................................................................. 150 mg Pyrantel (as embonate) ...................................................................... 50 mg Praziquantel ........................................................................................ 50 mg For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet. Yellow brown, oval tablet with a score line on both sides. The tablets can be divided into equal halves. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs (adults). 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Treatment of mixed infections by adult stages of cestodes and nematodes of the following species: Nematodes: Ascarids: _Toxocara canis_, _Toxascaris leonina_. Hookworms: _Uncinaria stenocephala_, _Ancylostoma caninum_. Whipworms: _Trichuris vulpis_. Cestodes: Tapeworms: _Taenia _spp., _Dipylidium caninum_. 4.3 CONTRAINDICATIONS Revised: December 2011 AN: 00108/2011 Page 2 of 6 Do not use in animals with a known sensitivity to the active ingredients or to any of the excipients. See section 4.7 below. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Dogs kept together or in kennels should be treated at the same time. Parasite resistance to any particular class of anthelmintic may develop followi ng frequent, repeated use of an a Izlasiet visu dokumentu